SCOTT GREENBERGER — Lobbyist Profile | Poliscope

SCOTT GREENBERGER

Reported covered position: N/A

Filings

Clients

Firms

Years active

2006–2007

Associated filing income

$90,000

How to read the money

Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.

Clients represented

Client	Filings	Years
SANOFI-AVENTIS U.S. INC.	2	2006–2007
TV 4 US	1	2006

Lobbying firms

Firm	Filings	Years
RICCHETTI INCORPORATED	3	2006–2007

Bills explicitly cited in this lobbyist’s assigned issues (5)

No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.

H.R. 1908

Patent Reform Act of 2007

Client: SANOFI-AVENTIS U S INC · Firm: RICCHETTI INCORPORATED

Open original LDA filing ↗

Cited source text

Issues related to the Patent Reform Act (S. 1145, H.R. 1908)

H.R. 194

Prescription Drug Affordability Act

Client: SANOFI-AVENTIS U S INC · Firm: RICCHETTI INCORPORATED

Open original LDA filing ↗

Cited source text

Issues related to PDUFA (The Prescription Drug User Fee Authorization Act) Issues related to drug importation (Prescription Drug Affordability Act/H.R. 194 and Pharmaceutical Market Access and Safety Drug Acts/S. 242, H.R. 380)

Original LDA source filings (3)

Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.

SANOFI-AVENTIS U S INC via RICCHETTI INCORPORATED

2007 · year_end · YA

Firm income: $90,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (4 issues)

ADV

Advertising

Issues related to direct-to-consumer marketing of drugs

MMM

Medicare/Medicaid

Issues related to the CHAMP Act (Children's Health and Medicare Protection Act) Issues related to Medicare coverage of drugs to treat obesity and cardio-metabolic risk Issues related to coding of drugs for treatment of osteoarthritis Issues related to treatment of prompt pay discounts in calculation of average sales price Issues related to the selection of approved compendia for determination of access to drugs Issues related to the bundling of payments for low-cost pharmaceuticals administered in outpatient settings

Source: Senate LDA